Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Escalation Study of MEDI-546 in Japanese Patients With Active Systemic Lupus Erythematosus
jRCT2080221785Phase 2
- Sponsor
- AstraZeneca
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of anifrolumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability of MEDI-546.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080221785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221785.